Navigation Links
Nile Therapeutics Announces Positive Results from Phase 1b Safety and Pharmacodynamics Study of CD-NP in Patients with Heart Failure
Date:12/9/2008

re patients frequently suffer episodes of acute decompensated heart failure (ADHF) which require hospitalization. For Americans over 65 years of age, ADHF is the most frequent cause of hospital admission. In recent years, 2.4 million patients in the US were hospitalized with a primary or secondary discharge code of ADHF and an average hospital stay of 4.3 days.

About CD-NP

CD-NP is a novel chimeric natriuretic peptide in clinical development for the treatment of ADHF. CD-NP was rationally designed by scientists at the Mayo Clinic's Cardiorenal Research Labs. Current therapies for ADHF, including B-type natriuretic peptide, have been associated with favorable pharmacologic effects, but have also been associated with hypotension and decreased renal function which limit their utility in clinical practice. CD-NP was designed to preserve the favorable effects of current therapies while preventing or attenuating the hypotensive response, and enhancing or preserving renal function. The Company believes that these biochemical features, together with preclinical and preliminary clinical data in patients with heart failure, suggest that CD-NP may have a favorable safety and efficacy profile relative to current therapies for ADHF. In addition to an initial indication for ADHF, CD-NP has potential utility in other indications which include preservation of cardiac function subsequent to acute myocardial infarction (AMI), and prevention of renal damage subsequent to cardiac surgery. We expect to initiate a Phase 2b study in patients with acute heart failure in 2009.

About Nile Therapeutics

Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical need. Nile is initially focusing its efforts on developing its lead compound, CD-NP, a novel rationally designed chimeric pept
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $32.65 Million of Senior Convertible Notes
2. Intradigm Announces Issuance of Key Patent Related to Enhancing Efficacy and Potency of RNAi Therapeutics
3. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
4. FDA Accepts Cell Therapeutics Zevalin sBLA and Grants Priority Review
5. Cell Therapeutics, Inc. (CTI) Zevalin Joint Venture Conference Call to be Webcast with Slides
6. Cell Therapeutics, Inc. (CTI) to Discuss Zevalin Joint Venture with Spectrum Pharmaceuticals
7. Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Drug
8. Aegera Therapeutics phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting
9. TorreyPines Therapeutics Enters into Agreement to Reduce Royalty Rates and Delay Clinical Milestone Payments Due to Eli Lilly for NGX426 and Tezampanel
10. Duska Therapeutics Provides Program Update and Reports Third Quarter 2008 Financial Results
11. Synvista Therapeutics Announces 510(k) Submission for Its HAPTOCHEK(TM) Test Kit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/p2ddnr/global_market ) ... of Trypsin" report to their offering. , ... providing comprehensive data on Trypsin globally and regionally ( ... North America , Latin America ... Trypsin This report focuses on three primary areas; ...
(Date:2/27/2015)... February 27, 2015 The fully ... (Nexera UC) can sequentially analyze up to 48 ... with high-sensitivity detection of targets by mass spectrometry. ... to fulfill the measurement requirements of a wide ... products, drug delivery and search for disease biomarkers, ...
(Date:2/27/2015)... -- Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company ... that it will be presenting at CALBIO 2015 at ... at 3pm PST. Patrick Lucy, chief business officer of ... state of the biosimilar industry landscape entitled The ... more information on CALBIO 2015 and The Evolving ...
(Date:2/27/2015)... 27, 2015 Cytokinetics, Incorporated (Nasdaq: CYTK) ... 28 with patients and health care advocates in the ... Disease Day®. Rare Disease Day is dedicated to ... to the special challenges faced by patients with rare ... is proud to stand alongside patients and caregivers representing ...
Breaking Biology Technology:Global Market Report of Trypsin 2014-2018 2Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 2Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 2Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 4Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 6
... Biosciences Corporation (Nasdaq: MATK ), a leader ... from microbial sources that promote health and wellness through ... the inaugural Small Business Innovation Research (SBIR) Hall of ... Martek Biosciences was recognized for its success in research, ...
... 17, 2011 CalciMedica, a biotechnology company developing ... today announced that it has dosed the first ... CM2489. CM2489 is a first-in-class calcium-release activated calcium ... oral therapeutic for patients with moderate-to-severe plaque psoriasis. ...
... the most effective weapons to stop the spread of cholera, ... since the devastating earthquake last year. A technique developed ... to test water sources that could be contaminated with the ... onto iron oxide nanoparticles and then added to a sample ...
Cached Biology Technology:Martek Biosciences Inducted into Small Business Innovation Research (SBIR) Hall of Fame 2Martek Biosciences Inducted into Small Business Innovation Research (SBIR) Hall of Fame 3CalciMedica Initiates Phase I Clinical Trial of First CRAC Channel Inhibitor (CCI) for Psoriasis 2Special sugar, nanoparticles combine to detect cholera toxin 2Special sugar, nanoparticles combine to detect cholera toxin 3
(Date:1/22/2015)... , Jan. 22, 2015 Research and Markets ... "Biometrics - A Global Market Overview" report to their ... technology is to ensure that an individual is who she/he ... may make use of a person,s unique physical characteristics, such ...
(Date:1/22/2015)... DETROIT , Jan. 13, 2015 Technology Showcase, Hall ... iris-based identity authentication solutions, today announced it will showcase its ... and developed by the Department of Energy,s Oak Ridge ... International Auto Show . EyeLock,s iris identity authentication technology is ...
(Date:1/22/2015)... POINT ROBERTS, Washington , January 20, 2015 ... including technology and tech stocks, releases video from the CES ... and security consultant Apollo Robbins . Apollo ... the Wocket™ biometric smart wallet, a product of NXT-ID, Inc. ...
Breaking Biology News(10 mins):Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3
... Commemorate JPMorgan Chase & Co. , Foundation Funding of ... , , ... Franklin McKinley School District and Bring Me A Book (BMAB) ... San Jose Elementary School Library Initiative in Franklin McKinley School District.  The ...
... the University of California, Riverside Norman Ellstrand ... been awarded 2010 Guggenheim Fellowships by the John ... appointed on the basis of achievement and exceptional promise. ... genetics, genomics, and the many faces of hybridization. Herrera, ...
... The U.S. Environmental Protection Agency today awarded more than ... the country who participated in the 6th Annual National ... D.C. The P3 award competition and National Sustainable ... of Earth Day, April 23-26. Winners of the EPA,s ...
Cached Biology News:JPMorgan Chase & Co., Invests $25,000 to Support Bring Me A Book's San Jose Elementary School Library Initiative 2JPMorgan Chase & Co., Invests $25,000 to Support Bring Me A Book's San Jose Elementary School Library Initiative 32 professors at UC Riverside receive Guggenheim Fellowships 22 professors at UC Riverside receive Guggenheim Fellowships 3EPA awards more than $1 million to college teams for environmental innovation 2
Mouse monoclonal [6C3] to JAB1 ( Abpromise for all tested applications). entrezGeneID: 10987 SwissProtID: O15386...
Human FGF R2 (alpha isoforms) MAb (Clone 98706)...
... Facilitates the simple, phenol-free extraction of genomic ... requiring proteinase K digestion.Each kit is designed ... preparations of up to 25 mg of ... Purification and Amplification of Genomic DNA, Nucleon ...
Request Info...
Biology Products: